• Accueil
  • Documentation
fr
Article scientifique
Anglais

Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease

Contributeurs/tricesAgosta, Federica; Altomare, Daniele; Festari, Cristina; Orini, Stefania; Gandolfo, Federica; Boccardi, Marina; Arbizu, Javier; Bouwman, Femke; Drzezga, Alexander; Nestor, Peter; Nobili, Flavio; Walker, Zuzana; Pagani, Marco
Publié dansEuropean Journal of Nuclear Medicine and Molecular Imaging, vol. 45, no. 9, p. 1546-1556
Date de publication2018
Résumé

To evaluate the incremental value of FDG-PET over clinical tests in: (i) diagnosis of amyotrophic lateral sclerosis (ALS); (ii) picking early signs of neurodegeneration in patients with a genetic risk of Huntington's disease (HD); and detecting metabolic changes related to cognitive impairment in (iii) ALS and (iv) HD patients.

Mots-clés
  • Amyotrophic Lateral Sclerosis/diagnostic imaging
  • Brain
  • Fluorodeoxyglucose F18
  • Humans
  • Huntington Disease/diagnostic imaging
  • Positron-Emission Tomography
  • Radiopharmaceuticals
Structure d'affiliation
Groupe de recherche
Citation (format ISO)
AGOSTA, Federica et al. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease. In: European Journal of Nuclear Medicine and Molecular Imaging, 2018, vol. 45, n° 9, p. 1546–1556. doi: 10.1007/s00259-018-4033-0
Fichiers principaux (1)
Article (Published version)
accessLevelRestricted
Identifiants
ISSN du journal1619-7070
352vues
0téléchargements

Informations techniques

Création04/01/2019 16:20:00
Première validation04/01/2019 16:20:00
Heure de mise à jour15/03/2023 15:43:04
Changement de statut15/03/2023 15:43:03
Dernière indexation17/01/2024 04:51:40
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack